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A real-time polymerase chain reaction (PCR) assay for
the direct identification ofMycobacterium tuberculosis
and M. bovis using molecular beacons was developed.
The assay was modified for use in regular thermal cy-
clers. Molecular beacons that were specific forM. tuber-
culosis (Tb-B) and M. bovis (Bo-B) were designed. The
fluorescence of the target PCR product-molecular bea-
con probe complex was detected visually using a tran-
silluminator. The results were then compared with
those of conventional multiplex PCR (CM-PCR) assays
and biochemical identification. The detection limit of
Tb-B and Bo-B beaconswas 500 fg and 50 fg by the visual
format and real-time PCR assay, respectively, compared
with 5 pg by CM-PCR assay. Pulmonary and extrapul-
monary samples were examined. The agreement be-
tween culture and the two assays was very good in
sputum samples and fair in extrapulmonary samples.
The agreement between clinical diagnoses with the
two assays was moderate in extrapulmonary samples.
There was very good agreement between CM-PCR
and visual format assays for all samples used in the
study. Concordance in the identification of isolates
by the visual , CM-PCR assay, and biochemical iden-
tification was seen. Hence, the use of molecular
beacon detection of M. tuberculosis and M. bovis in
clinical samples is feasible by setting up two asym-
metric PCRs concurrently. The assay is sensitive ,
specific , simple to interpret , and takes less than 3
hours to complete. (J Mol Diagn 2009, 11:430–438; DOI:
10.2353/jmoldx.2009.080135)
For effective treatment of tuberculosis (TB), rapid and
accurate diagnosis is essential. Conventional polymer-
ase chain reaction (PCR)-based assays designed to de-
tect Mycobacterium tuberculosis that involve electro-
phoresis based analysis of amplicons are relatively fast
but are laborious and the potential risk of inadvertent
dispersal of amplicons leading to contamination of un-
tested samples exists. To overcome these difficulties a
number of probes, including TaqMan probes, molecular
beacons, and side-by-side probes, that can report the
amplification of the correct amplicon in sealed tubes
have been developed.1–3 Several different instruments
that measure increase in fluorescence of these probes
while simultaneously performing amplification have also
become available. Although such real-time PCR assays
are more quantitative than conventional ones, the instru-
ments used are not commonly available in resource-poor
locations. Since such localities are often where tubercu-
losis is more prevalent, it is important to develop sealed
tube assays that can be implemented on conventional
PCR machines but have the simplicity and accuracy of
probe-based detection.
In the previously developed tests different coding and
intergenic regions from theM. tuberculosis genome, such
as devR, IS6110, IS986, RNA polymerase gene, and
ribosomal RNA gene have been used as targets for ampli-
fication using molecular beacons or fluorescent probes.4–7
One of the limitations of these tests is that they have exclu-
sively focused on M. tuberculosis. However, other closely
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related bacteria such as M. bovis have been often associ-
ated clinically with human and bovine samples in prac-
tice.8–10 Therefore an ideal test should distinguish between
M. tuberculosis andM. bovis. We used themce3 operon that
has a differential organization in the M. tuberculosis and M.
bovis genome as a suitable target for the assay.11
To develop a simple sealed tube test that can reliably
detect M. tuberculosis in clinical samples using conven-
tional PCR instrument for amplification and a common
lamp for transillumination, we used molecular beacons as
probes. However, the signal intensity in PCRs performed
with molecular beacons is often limited because the two
product strands of the amplicon bind to each other ex-
cluding the probe from the target strand. We improved
the fluorescence intensity of these reactions by perform-
ing asymmetric PCR that produced more of the molecular
beacon target strand than of the opposite strand. The
optimizations were performed using a real-time instru-
ment. We show that our assay is robust, specific, sensi-
tive, and can be completed in less than 3 hours. The
presence of mycobacteria in the sample can be conclu-
sively established by visualizing the fluorescent amplicon
in a blue light transilluminator by the naked eye. We also
compared and correlated our endpoint visual format assay
with acid-fast bacilli (AFB) smear microscopy; a gel-based
conventional multiplex PCR (CM-PCR) assay, culture, and
clinical diagnosis. The simplified visual format assay was
found to be an accurate predictor of the presence of M.
tuberculosis and M. bovis in clinical samples.
Materials and Methods
Samples
Sputum samples were collected from 97 pulmonary tu-
berculosis patients attending the outpatient department
of LRS Institute of tuberculosis and Respiratory Disease,
New Delhi. Seventy-one aseptically aspirated pleural
fluid samples were obtained from patients registered in
the Department of Respiratory Medicine, Safdarjung Hos-
pital, New Delhi. The study was approved by the institu-
tional ethical committee. The clinical criteria as described
by Light12 were adopted for the diagnosis of pleural
tuberculosis. The definitive criterion for tuberculous pleu-
ral effusion was the demonstration of acid-fast bacilli in
sputum and or pleural fluid by microscopy or culture.
Suggestive criteria included: 1) patients with clinical his-
tory of fever, pleuritic chest pain, cough, breathlessness,
and chest radiography with evidence of pleural effusion;
2) cytological examination of the pleural fluid for predom-
inance of lymphocytes and paucity of mesothelial cells;
3) biochemical estimation for protein content (3 g/dl) in
pleural fluid: serum protein ratio (0.5); and 4) response
of patients to antituberculous treatment. Tuberculous
pleural effusion was diagnosed if the definitive criterion or
all of the suggestive criteria were met. Based on these
criteria, 51 patients were classified as patients with tu-
berculous pleural effusion.
Criteria for including malignant pleural effusion pa-
tients (controls) were: clinical history suggestive of rap-
idly refilling pleural effusion with or without focal malig-
nant lesion elsewhere in the body; pleural fluid being
exudative, usually hemorrhagic; and on cytological ex-
amination, positive for malignant cells. Based on these
criteria 20 patients were classified as nontuberculous
pleural effusion patients (non-TB).
The cerebrospinal fluid (CSF) sample was obtained
from a clinically suspected case of tuberculous meningi-
tis. The patient was admitted to the pediatric ward at
Kalawati Saran Children Hospital, New Delhi.
Processing of Samples
All samples except CSF were processed by the NALC-
NaOH method.13 For processing of CSF, the filtration
method was used as described earlier.14The sediments
were processed for AFB microscopy, isolation of myco-
bacteria, and target DNA. A total of 118 samples (97
sputum, 20 pleural fluid, and the CSF sample) were in-
oculated into MGIT tubes (BD BACTEC MGIT 960 system
for mycobacteria testing). The remaining 51 pleural fluid
samples were inoculated on Lowenstein-Jensen medium
and into 7H9 broth. All cultures were examined up to 8
weeks. Species level identification of isolates was done
by standard biochemical tests (niacin production, nitrate
reduction, catalase and aryl sulfatase activity, Tween
hydrolysis, thiopen-2-carboxylic acid hydrazide sensitiv-
ity) as recommended by the Centers for Disease Control
and Prevention, Atlanta, GA, with appropriate controls.15
Mycobacterial Strains
M. tuberculosis (M. tuberculosis, H37Rv) DNA was ob-
tained from Tuberculosis Research Material, NIAD, Na-
tional Institutes of Health. M. bovis (AN5) was obtained
from National JALMA Institute for Leprosy and Other
Mycobacterial Diseases, Agra, India.
Design and Characterization of the Molecular
Beacons
M. tuberculosis beacon (Tb-B) was designed targeting
the unique 12.7-kb fragment of the M. tuberculosis ge-
nome. The M. bovis beacon (Bo-B) was designed com-
mencing 1 bp 5 to the deletion site of the 12.7-kb frag-
ment in the M. bovis genome. The positions of the
beacons and primers are shown in Figure 1.11
Figure 1. Position of primers and beacons in themce3 operon11 used for the
detection and identification of M. tuberculosis and M. bovis. 12.7-kb insert
prevents Taq polymerase-mediated amplification in M. tuberculosis, hence
amplification seen only in M. bovis.
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Thermal denaturation profile studies were conducted
to determine the optimal annealing temperature for the
real-time PCR. Real-time PCR was done as follows: mo-
lecular beacon buffer alone (negative control); buffer 
Tb-B (negative control); buffer  Tb-B  target oligonu-
cleotide ofM. tuberculosis (TO-tb, positive control); buffer
Tb-B  target oligonucleotide M. bovis (TO-bo). Identical
combination of reagents was used with M. bovis beacon
(Bo-B). For the assay the molecular beacon buffer (3.5
mmol/L MgCl2 and 10 mmol/L Tris-HCl), with 0.3 mol/L
each of molecular beacon (Tb-B and Bo-B) and 0.6
mol/L each of target oligonucleotide (5-GTACTATGCT-
GACCCATGCGCCCT-3 and TO-Bo, 5-CGGAGAGCG-
CCGTTGTAGGCC-3) was used. Target oligonucleotides
contained the complementary sequence of the beacon’s
loop. Each tube was subjected to sequential decrease in
temperature (1°C at a time) from 96 to 45°C. Fluores-
cence was estimated during the 30-second hold period
at each temperature in the real-time thermal cycler. The
melt curve of the molecular beacons was obtained by
plotting a –dF/dT curve.
The signal-to-noise ratio of the molecular beacons was
determined by measuring the fluorescence at 491 nm
excitation and 515 nm emission in a spectrofluorimeter
(Spectra MAX Gemini XS, Molecular Devices). Back-
ground fluorescence of the buffer and beacons was as-
sessed and deducted from the fluorescence estimated
following target hybridization. The signal-to-noise ratio
(STNR) of the molecular beacons was determined as
follows: STNR  Fopen – Fbuffer/Fclosed – Fbuffer, where
Fbuffer  fluorescence of molecular beacons buffer (con-
taining 1 mmol/L MgCl2  20 mmol/L Tris-HCl, pH 8);
Fclosed  fluorescence of 0.3 mol/L molecular beacons
in the molecular beacons buffer; Fopen  fluorescence of
molecular beacon buffer containing 0.3 mol/L molecular
beacons and 0.6 mol/L target oligonucleotide.
The readings obtained with M. tuberculosis beacon
were as follows: molecular beacon buffer was Fbuffer 
5.4, for M. tuberculosis beacon with buffer Fclosed 
136.2, M. tuberculosis beacon with target oligonucleotide
of M. tuberculosis Fopen  3055.1. Similarly for M. bovis
beacon the reading obtained was as follows: buffer alone
Fbuffer  4.4, for M. bovis beacon with buffer Fclosed 
38.1, M. bovis beacon with target oligonucleotide of M.
bovis Fopen  905.6. The signal-to-noise ratio of the re-
spective molecular beacons was 27 and 23 for M. bovis
and M. tuberculosis beacons, respectively. These char-
acterizations were performed at the room temperature.
The signal to noise ratio for the beacons were determined
with twofold increase in target oligonucleotide by the
fluorometric and visual format methods.
PCR Assay
The assay was first standardized in a real-time format
(FP, forward primer common to both M. tuberculosis and
M. bovis; RPT, reverse primer from 12.7-kb fragment spe-
cific for M. tuberculosis; RPC, reverse primer from the se-
quence present in bothM. tuberculosis andM. bovis). ForM.
tuberculosis the primers used were FP (5-ATGACGCCTTC-
CTAACCAGAA-3) and RPT (5-ATGCATCGGAATAAGAT-
GTCAGGC-3) with Tb-B (FAM-5-CCGCGGAGGGCG-
CATGGGTCAGCATAGTACCGCGG-3-BHQ2) and for M.
bovis the primers used were FP and RPC (5-ACCGGA-
TATCTTAGCTGGTCAA-3) with Bo-B (FAM-5-CCGCGC-
TGGCCTACAACGGCGCTCTCCGCGCGG-3–BHQ2).
Sequences in italic demarcate the beacon stem. Subse-
quently the real-time format assay was modified for the
visual format. The visual format assay was compared with
the CM-PCR assay.
Real-Time PCR Assay
The experiments were performed with an iCycler iQ
real-time detection system (Bio-Rad). For the asymmetric
PCR assay, two reaction mixtures were set up for detec-
tion of M. tuberculosis and M. bovis. The first mixture (50
l reaction) contained the primer FP (0.1 mol/L) and
RPT (0.5 mol/L) and the Tb-B (0.6 mol/L). The second
mixture (50 l reaction) contained the FP and RPC (0.5
mol/L) and the Bo-b (0.6 mol/L). The PCR reaction
mixture contained 1X AmpliTaq Gold PCR buffer, 4
mmol/L MgCl2, 0.25 mmol/L dNTPs (Eppendorf), and 2.5
U AmpliTaq Gold enzyme (Applied Biosystems). The
thermal cycle parameters were 95°C for 10 minutes and
40 cycles of each for 45 seconds at 95°C, 45 seconds at
the optimized annealing temperature, 45 seconds at
72°C, and final extension at 72°C for 10 minutes. Anneal-
ing temperature for asymmetric PCR assay was deter-
mined by the melt curve analysis of the beacons with their
target oligonucleotides.
Visual Format Using Molecular Beacons
The asymmetric PCR parameter and conditions in the
visual format were identical to the real-time PCR assay
with the exception of the Taq polymerase enzyme (MBI
Fermentas) in place of AmpliTaq Gold enzyme.
Multiplex PCR
Three primers were used: FP common to M. tubercu-
losis andM. bovis and two reverse primers, RPT and RPC,
specific for M. tuberculosis and M. bovis, respectively.
The assay mixture (25 l reaction) contained FP (0.625
mol/L), RPT and RPC (0.325 mol/L each), 1X PCR
buffer (100 mmol/L Tris/HCl, pH 8.8, 500 mmol/L KCl,
0.8% Nonidet P-40), 2.5 mmol/L MgCl2, 0.3 mmol/L
dNTPs, and 1.25 U TaqDNA polymerase. The thermal
cycle parameters were 95°C for 10 minutes and 40 cy-
cles of each, 45 seconds at 95°C, 45 seconds at 58°C, 45
seconds at 72°C, and final extension at 72°C for 10
minutes. The standardized assay was used for detection
of M. tuberculosis as well as M. bovis in clinical samples.
The amplified product obtained in CM-PCR assay is 162
and 127 bp forM. tuberculosis andM. bovis, respectively.
Detection of PCR-Amplified Product
For the gel-based CM-PCR, amplicon(s) were detected
by standard ethidium bromide staining and ultraviolet
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illumination of 2.2% agarose gels. For the visual format
using molecular beacons, tubes were positioned over a
dark reader box (Clare Chemical Research). Tubes were
illuminated with a source of visible excitation blue light
devoid of ultraviolet radiation. An amber screen sepa-
rated the light source from the viewer. The fluorescence
was viewed and assessed in the dark by at least two
individuals.
Sensitivity of the Assays
The limit of sensitivity of the PCR assays (real-time PCR,
CM-PCR, and molecular beacons using visual format)
was determined by serial dilutions of M. tuberculosis and
M. bovis DNA.
Statistical Analysis
All statistical analyses were done using STATA software,
version 9.2 (StataCorp, College Station, TX). The agree-
ment between the assays used was assessed using the
kappa coefficient (). The strength of agreement was
defined as: poor,   0.2; fair,   0.21–0.4; moderate,
  0.41–0.6; good,   0.61–0.8; very good,  
0.81–1.16
Results
Rationale for the PCR Target Used in the Study
Sequence analysis of M. tuberculosis and M. bovis has
shown that M. bovis lacks the 12.7-kb fragment contain-
ing the mce3 operon.11 All M. tuberculosis isolates exam-
ined showed the presence of the 12.7-kb fragment, while
all of the M. bovis strains lacked this fragment.11 We
exploited the differences in the organization of the mce3
operon in the two species.11 Primers were designed as
follows: FP was common to both M. tuberculosis and M.
bovis; RPT was derived from the 12.7-kb fragment and
RPC from the region adjacent to the 12.7-kb fragment
(Figure 1).11 RPT primer was specific for M. tuberculosis,
while the sequence of the RPC reverse primer was
present in both M. tuberculosis and M. bovis. However,
amplification occurs in case of M. bovis with the FP and
RPC exclusively and not in the case ofM. tuberculosis, as
the 12.7-kb insert prevents Taq polymerase-mediated
amplification.
Characterization of Molecular Beacons
The beacons were characterized by visual and fluoromet-
ric techniques. The specificity of molecular beacons was
assessed by adding excess of the target oligonucleo-
tides and an aliquot of each molecular beacon. Photo-
graphs were taken. Figure 2A shows that M. tuberculosis
target oligonucleotide elicited fluorescence with Tb-B
and M. bovis target oligonucleotide elicited fluorescence
with Bo-B and not vice versa. In absence of the target
oligonucleotides, no fluorescence was generated by the
molecular beacons in the tubes. The signal-to-noise ratio
of the respective molecular beacons was determined as
described in Materials and Methods. The signal-to-noise
ratio of the respective molecular beacons was 27 and 23
for M. bovis and M. tuberculosis beacons, respectively.
Further, the thermal denaturation profile for each mo-
lecular beacon was determined by real-time PCR. As
shown in Figure 2B, the probe target hybrid for M. tuber-
culosis beacon melts at 58°C and that ofM. bovismelts at
56°C, and the stems of each molecular beacon melt at a
Figure 3. Amplification plots show the detection of the serially diluted DNA
of M. tuberculosis (A) and M. bovis (B) by real-time PCR using molecular
beacons. Tenfold serial dilution of the mycobacterial DNA, ranging from 5 
106 to 5 bacilli/reaction (from left to right) and the negative control were
amplified in individual tubes. PCR cycles have been plotted against fluores-
cence intensity.
Figure 2. A: Signal-to-noise ratio of molecular beacons. The signal-to-noise
ratio of M. tuberculosis and M. bovis beacons was determined by the visual
format assay. Tube 1, buffer (negative control); tube 2, buffer  M. tuber-
culosis beacon (negative control); tube 3, buffer  M. tuberculosis beacon 
target oligonucleotide of M. tuberculosis (positive control); tube 4, buffer 
M. tuberculosis beacon  target oligonucleotide of M. bovis; tube 5, buffer
(negative control); tube 6, buffer  M. bovis beacon (negative control); tube
7, buffer  M. bovis beacons  target oligonucleotide M. bovis (positive
control); tube 8, buffer  M. bovis beacon  target oligonucleotide M.
tuberculosis. B: Thermo-denaturation profile for molecular beacons. Dotted
line denotes M. bovis beacon with its target oligonucleotide melt curve.
Continuous line denotes M. tuberculosis beacon with its target oligonucleo-
tide melt curve. All other lines denotes various controls.
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range between 74 and 76°C. These features indicate that
the detection temperatures can be below 60°C, at which the
probe-target hybrids would be allowed to form when the
target is produced in the reaction and the stems would
remain closed when the target is absent.
Real-Time PCR and Multiplex PCR Sensitivity
As the signal intensities generated by real-time PCR were
inadequate, asymmetric PCR was performed to intensify
and maximize the fluorescence. To demonstrate the limits
of detection of M. tuberculosis and M. bovis, serial dilu-
tions of the DNA ranging from 500 ng to 10 fg were added
to the asymmetric PCR reaction. Two separate reactions
were set up using Tb-B and Bo-B. The limit of detection
by real-time PCR is shown in Figure 3, A and B. The
detection limit with Tb-B and Bo-B beacons was 500 fg
(50 bacilli) and 50 fg (5 bacilli), respectively. The sensi-
tivity of the visual format using molecular beacons was
similar to that detected by real-time PCR (Figure 4A).
Gel-based CM-PCR assay showed lower sensitivity of
detection of mycobacterial DNA (5 pg, equivalent to 500
bacilli; Figure 4B).
Comparative Analysis of the Four Methods for
Detection of Mycobacteria in 97 Sputum
Samples
Four methods were used for detecting mycobacteria in
sputum samples: AFB smear microscopy, isolation by
culture, visual format using molecular beacons, and
CM-PCR assays (Table 1). The results of the detection of
AFB by smear microscopy were compared with culture,
Figure 5. A: CM-PCR for detecting and differentiating M. tuberculosis and M.
bovis in the CSF sample, CS-112. The ethidium bromide stained amplification
products of M. tuberculosis and M. bovis generated by using FP, RPT, and
RPC primers were electrophoresed on 2.2% agarose gel. The 162- and 127-bp
products obtained in M. tuberculosis and M. bovis respectively, are indicated.
Lane 1, PF-7; lane 2, CSF; lane 3, M. tuberculosis (positive control, H37Rv);
lane 4, M. bovis (positive control AN-5); lane M, 50-bp molecular weight
marker; lanes 6 and 7, negative control. B: Visual format using molecular
beacons for detecting and differentiating M. tuberculosis and M. bovis in the
CSF sample, CS-112. Tubes 1–4 showing fluorescence obtained using primer
pair FP and RPT with M. tuberculosis beacon and tubes 5–8 showing
fluorescence obtained using primer pair FP and RPC with M. bovis beacon.
Tubes 1 and 5, PF-7; tubes 2 and 6, CSF; tube 3, M. tuberculosis positive
control; tube 7, M. bovis positive control; tubes 4 and 8, negative control.
Figure 4. Limit of detection of M. tuberculosis and M. bovis DNA by PCR
assay using molecular beacons by the visual format (A) and gel-based assays
(B). M. tuberculosis and M. bovis DNA were added as follows: tube 1, 50 ng
(5 106 bacilli); tube 2, 5 ng (5 105 bacilli); tube 3, 500 pg (5 104 bacilli);
tube 4, 50 pg (5  103 bacilli); tube 5, 5 pg (5  102 bacilli); tube 6, 500 fg
(5  101 bacilli); tube 7, 50 fg (5 bacilli); tube 8, negative control in visual
format; tube 8, 5 fg (1 bacilli) in gel-based; tube 9, negative control.
Table 1. Comparative Analysis of AFB Smear Microscopy of Sputum Samples with Isolation of Mycobacteria by Culture, Visual
Format, and CM-PCR Assay
Assays
AFB Total
(n  97)
 (P value)*
P (n  45) N (n  52)
Culture versus
assays
Culture versus
AFB Visual versus CM-PCR
Culture†
P 45 33 78 0.35 (0.001) 0.89 (0.001)
N 0 19
Visual format‡
P 45 30 75 0.91 (0.001)
N 0 22
CM-PCR
P 45 26 71 0.80 (0.001)
N 0 26
*Agreement between the assays calculated using STATA software version 9.2.
†Inoculated in MGIT tubes, incubated at 37°C for 6–8 weeks.
‡Detection of M. tuberculosis and M. bovis using beacons.
P, positive; N, negative.
434 Kumar et al
JMD September 2009, Vol. 11, No. 5
visual format, and CM-PCR assays. Of the 97 sputum
samples processed, in 45 samples (45/97, 46.3%) AFB
was detected. All 45 AFB smear positive samples were
positive by the three methods used, namely culture, vi-
sual format, and CM-PCR assays. Among the 52 AFB
negative samples, in 33 samples mycobacteria were iso-
lated by culture. By the visual format assay 30 of the 52
(57.6%) and by the CM-PCR assay 26 of the 52 (50%)
samples were positive for M. tuberculosis. On comparing
these assay results with culture, in the visual format assay
using molecular beacons and CM-PCR assay a very
good agreement was seen (  0.91 and 0.80 respec-
tively; Table 1). Between the visual format and CM-PCR
assays there was near perfect agreement (  0.89).
However, between culture and AFB detection by smear
microscopy, the agreement was limited (  0.35).
Comparative Analysis of the Four Methods
for Detection of Mycobacteria in Pleural
Fluid Samples
Mycobacteria in pleural fluid samples were detected by
the four methods described (Table 2). The results ob-
tained by these methods were compared, with isolation of
mycobacteria by culture and clinical diagnosis. The dis-
tribution of these 71 samples is detailed in Table 2.
Of the 51 clinically diagnosed pleural tuberculosis pa-
tients, mycobacteria were detected in 17 samples
(33.3%) either by AFB microscopy or by culture. No
mycobacteria were detected in non-TB patients by any of
the assays used. By the visual format and CM-PCR as-
says M. tuberculosis was detected directly in 11 of the 13
culture positive samples. In two samples negative by
both the visual format and CM-PCR assays, the myco-
bacteria isolated from these samples were identified as
M. fortuitum andM. chelonae, respectively. In culture neg-
ative samples, 24 (24/38, 63.1%) samples were positive
for M. tuberculosis by the visual format assay, compared
with 20 (20/38, 52.6%) samples that were positive by the
CM-PCR assay (Table 2). There was fair to moderate
agreement among the results obtained by the two assays
(visual format and CM-PCR assays) compared with cul-
ture and clinical diagnoses except with AFB smear mi-
croscopy. Fair agreement between culture and visual
format and culture and CM-PCR assays was observed
(  0.26 for visual format and 0.33 for CM-PCR assay,
respectively). Between clinical diagnosis and the assays
used, moderate agreement was observed (  0.55 for
visual format and 0.47 for CM-PCR assay, respectively).
In 35 of the 51 (68.6%) samples mycobacteria were
detected by the visual format assay compared with 31
(60.7%) by the gel-based assay, 13 (25.5%) by culture,
and 7 (13.7%) by AFB smear microscopy. Poor agree-
ment was seen between AFB detection and culture and
AFB detection and clinical diagnosis (  0.20 and 0.08,
respectively). Agreement between the visual format and
CM-PCR assays was very good (  0.89).
Detection of Mixed Infection in CSF Sample
Clinically Suspected of Tuberculous Meningitis
The CSF sample was processed as described previously.14
The CSF sample was filtered, and the residue on the filter
(0.45 m) membrane was directly used for detection of M.
tuberculosis and/M. bovis by culture (BACTECMGIT960) as
well as by the assays described herein. Using molecular
beacons (visual format assay) (Figure 5B) and CM-PCR
assay, the sample was positive forM. tuberculosis as well
asM. bovis (Figure 5A). The dual PCR-amplified products
seen in the sample align to the 162- and 127-bp products
obtained in the standard strains ofM. tuberculosis andM.
bovis (positive controls), respectively. Two weeks later,
the MGIT culture of the CSF sample was similarly positive
for both pathogens. The assays have been performed
three times to confirm the results. Efforts are under way to
Table 2. Comparative Analysis of Clinical Diagnosis and Isolation of Mycobacteria from Samples Derived from Pleurisy Patients
with AFB Smear Microscopy, Visual Format, and CM-PCR Assay
Assay method
Clinical diagnosis*
 (P value)†
TB patients
(n  51)
Culture‡
Non-TB patients
(n  20)
Culture Culture versus
assays
Clinical diagnosis
versus assays
Culture versus
clinical diagnosis
Visual versus
CM-PCRP 13 N 38 P 0 N 20
Visual format§
P 11 24 0 0 0.26 (0.01) 0.55 (0.001) 0.16 (0.01) 0.89 (0.001)
N 2¶ 14 0 20
CM-PCR
P 11 20 0 0 0.33 (0.001) 0.47 (0.001)
N 2¶ 18 0 20
AFB
P 3 4 0 0 0.20 (0.04) 0.08 (0.04)
N 10 34 0 20
*Clinical diagnosis of TB and non-TB patients based on criteria detailed in Materials and Methods.
†Agreement between the assays calculated using STATA software version 9.2.
‡Culture: sample inoculated into MGIT/LJ/7H9, incubated at 37°C for 6–8 weeks.
§Detection of M. tuberculosis and M. bovis using beacons.
¶MOTT isolates M. fortuitum and M. chelonae.
P, positive; N, negative.
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separate the AFB obtained in MGIT media on 7H11 Du-
bos agar.
Agreement between Direct Detection of
Mycobacteria in Clinical Samples by Multiplex
PCR Assay and the Visual Format Beacon
Assay Versus Classical Identification of Isolates
Seventy-eight isolates were obtained from 97 sputum and
13 from 51 pleural tuberculosis patients. All isolates were
AFB positive and were identified by biochemical crite-
ria.15 Of the 91 isolates, 89 were identified as M. tuber-
culosis with the exception of two isolates from pleural
tuberculosis patients. These two isolates were identified
as M. fortuitum and M. chelonae. The mixed culture ob-
tained from the CSF sample in MGIT media has been
subcultured on 7H11 Dubos agar to isolate and charac-
terize the strain(s) by standard biochemical tests. There
was complete concordance in the direct identification of
mycobacteria present in the clinical sample before isola-
tion by the visual format and CM-PCR assays. M. fortui-
tum and M. chelonae was isolated from the pleural tuber-
culosis patients that were negative by both assays. The
20 DNA samples derived fromM. bovis isolates (courtesy
Dr. Niamh Corbally) were identified as M. bovis by both
assays.
Discussion
The molecular beacon-based PCR assay described has
the potential for direct detection of specific mycobacterial
pathogens, namely M. tuberculosis and M. bovis, that
could potentially be present in clinical samples. In the
visual format assay, a sample was considered positive if
the fluorescence intensity was more than the negative
control (without DNA). In comparison with culture, the
visually configured assay using molecular beacons de-
scribed in this study showed the sensitivity of 96.1%
compared with earlier reports of 86.7% for devR and
88.3% for IS6110 PCR.4 To the best of our knowledge,
this is the first report of molecular beacons used in com-
bination with asymmetric PCR for detection of dual infec-
tion due to M. tuberculosis and M. bovis in a sample. This
confirms our earlier report using the hupB-based assay17
describing dual detection of M. tuberculosis and M. bovis
in clinical samples. Similar reports of mixed mycobacte-
rial infection in individual clinical samples have been
described.18–20
The classical microbiological methods for diagnosing
tuberculosis have poor sensitivity and specificity.21 Tra-
ditionally, the diagnosis of tuberculosis depends on dem-
onstration of mycobacteria by AFB smear microscopy
and growth on Lowenstein-Jensen medium. AFB micros-
copy is rapid; the results are obtained within a few min-
utes compared with the 2- to 6-week time period required
by the MGIT-960 culture system.22,23 AFB microscopy is
inexpensive, easy to perform, and requires limited train-
ing and equipment. The major disadvantage of smear
microscopy is its sensitivity, as a smear to be considered
positive should have a concentration of 10,000 AFB/
ml.24,25 The low sensitivity is often reflected by the high
rates of smear-negative TB cases.4 On the other hand,
there have been some improvements in the culture-
based detection systems, but the requirement of expen-
sive instrumentation (such as BACTEC-460, MGIT-960)
has restricted their use to specialized laboratories. My-
cobacterial culture is more sensitive compared with
smear microscopy, as 10 to 100 bacilli/ml are required for
culture-based detection.24,25 Our method is similar in its
simplicity compared with smear microscopy but has im-
proved sensitivity and specificity, requiring 5 to 50 bacilli
for detection by the visual format assay.
Due to the inherent paucibacillary nature of pleural
fluid samples, the isolation of mycobacteria by culture
has been inefficient.26,27 The rate of isolation of myco-
bacteria from pleural fluid has been reported to range
from 12% to 33%.26,28,29 Besides pleural fluid, inclusion
of sputum samples has been considered appropriate to
improve the demonstration of mycobacteria by smear
microscopy and its isolation28 (submitted for publication
by P Kumar, MK Sen, DS Chauhan, VM Katoch, S Singh,
HK Prasad). In the present study in 17 of the 51 (33.3%)
samples derived from pleural TB patients, AFB was de-
tected in seven samples and mycobacteria were isolated
from 13 (Table 2). These patients meet the definitive
criterion for tuberculous pleural effusion. Fifteen of these
17 samples (88.2%) were positive by the visual as well as
the CM-PCR assay for M. tuberculosis. Besides the defin-
itive criterion, 34 patients met the suggestive criteria for
tuberculous pleural effusion, such as clinical history of
fever, chest pain, cough, breathlessness, and chest ra-
diography with evidence of pleural effusion and pleural
fluid cytology commensurate with pleural TB and re-
sponded to antituberculous treatment. In 70% of these (24/
34) patients M. tuberculosis was detected by the visual
format assay. PCR-based detection of M. tuberculosis in
smear negative samples has been reported.30 Further, im-
provement of detection and isolation of mycobacteria in
pleural effusion patients has been reported with inclusion
of pleural biopsies.29,31 However, this approach is disad-
vantaged owing to its invasiveness, complications of the
procedure, and the inability to sample infectious foci of
the pleural tissue.
Besides demonstration of mycobacteria in patient-de-
rived samples, the detection of mycobacterial DNA in
clinical samples using PCR has been widely adopted as
a rapid, sensitive, and specific diagnostic method.32 Use
of the nested PCR assay has provided a remarkable
increase in sensitivity and specificity of DNA amplification
compared with the conventional single-step PCR as-
say.18,33,34 However, the nested PCR assay is laborious
and time-consuming, which carries the risk of contami-
nation in clinical samples. Hence it has yet to be widely
used in tuberculosis diagnosis.33,34 To overcome the
problems of sample contamination and to reduce detec-
tion time, real-time PCR technique has been developed
as an alternate rapid and sensitive assay for detection of
M. tuberculosis in clinical samples.35,36 Although real-
time PCR assay has qualitatively advanced microbial
detection assays, owing to their technological sophisti-
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cation, equipment and reagent costs have restricted its
utility in the diagnosis of infectious diseases for special-
ized laboratories.
The simplicity of the assay and visual interpretation
makes it ideally suited for routine use in clinical labora-
tories with limited resources, such as in developing coun-
tries. The assay could be further simplified from the
present format by using molecular beacons tagged with
different fluorophores in a multiplex assay.37 Such a mul-
tiplex assay would reduce the number of tubes, time,
labor, and cost required to set up an assay for a clinical
sample. However, the clinical samples suspected of dual
infection must necessarily be investigated and analyzed
using the visual format assay as outlined in this study.
Cross-contamination with PCR products does not occur,
as assay tubes are not opened after amplification. The
study shows that simple end point detection using mo-
lecular beacons and a blue light transilluminator has a
great potential in the clinical diagnosis of tuberculosis
and that of other pathogens.
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